Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

Phase 2 Completed 21 enrolled University of Arkansas Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment. Secondary objectives include the subject's time in weeks from treatment onset to documented disease progression as assessed by the RECIST criteria, response rate, median and overall survival, safety and tolerability.

Timeline

Start: 2006-02
Primary completion: 2010-09
Completion: 2010-09

Publications

Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol. 2013 Jun;36(3):254-7. doi: 10.1097/COC.0b013e318248d83f.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Erlotinib	Small molecule	150 mg	Oral

Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

Summary

Timeline

Publications

Drugs

Indications